RARENasdaqPharmaceutical PreparationsFiscal year ends December 31

Ultragenyx Pharmaceutical Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$15.07+0.53 (+3.65%)

Close on Oct 19, 2026

Market cap: $1.54B
P/E (TTM): –
Dividend yield: –

Ultragenyx Pharmaceutical Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Revenue	673	560	434	363	351	271	104	51	2.61	0.13	–	–	–	–
Cost of Revenue	–	–	–	–	–	–	–	1.15	0.00	–	–	–	–	–
Gross Profit	–	–	–	–	–	–	–	50	2.61	–	–	–	–	–
Research & Development	750	698	648	706	497	412	357	294	232	183	115	46	28	13
Selling, General & Admin	349	321	310	278	220	183	162	128	100	65	33	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	65	33	11	4.45	3.34
Operating Expenses	–	–	–	–	–	601	528	423	332	248	148	57	32	16
Operating Income	-535	-536	-569	-649	-382	-330	-424	-371	-329	-248	-148	-57	-32	-16
Interest & Investment Income	25	37	27	11	1.93	7.04	13	9.54	4.07	3.79	2.32	0.61	0.22	0.00
Other Non-Operating Income	1.00	-5.00	-1.00	-1.57	-1.69	0.61	-0.79	-5.59	6.53	-1.62	-0.20	-3.02	-2.79	-0.35
Asset Impairment Charges	–	–	–	–	0	0	0	0	–	–	–	–	–	–
Gain (Loss) on Investments	–	-1.12	0.40	-19	-42	170	13	–	–	–	–	–	–	–
Pretax Income	-571	-567	-609	-702	-453	-185	-399	-197	-318	-246	-146	-60	–	–
Income Tax Expense	4.00	2.00	-2.00	5.70	1.04	1.21	3.28	0.51	-16	0.04	0	0	0	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	-187	-403	-198	-302	-246	–	–	–	–
Net Income	-575	-569	-607	-707	-454	-187	-403	-198	-302	-246	-146	-60	-35	-16
Net Income to Common	–	–	–	–	–	–	–	–	–	-246	-146	-65	-50	-20
EPS (Basic)(per share)	-5.83	-6.29	-8.25	-10.12	-6.70	-3.07	-7.12	-3.97	-7.12	-6.21	-3.96	-2.25	-14.87	-14.20
EPS (Diluted)(per share)	-5.83	-6.29	-8.25	-10.12	-6.70	-3.07	-7.12	-3.97	-7.12	-6.21	-3.96	-2.25	-14.87	-14.20
Shares Outstanding (Basic, Weighted)(shares)	99	91	74	70	68	61	57	50	42	40	37	29	3.58	3.12
Shares Outstanding (Diluted, Weighted)(shares)	99	91	74	70	68	61	57	50	42	40	37	29	3.38	1.38
Dividend per Share(per share)	–	–	–	–	–	–	–	–	–	–	0.00	0.00	–	–
EBITDA	-500	-500	-543	-631	-368	-318	-416	-352	-323	-245	-146	-56	-32	-16

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -73.6%
Net margin: -81.7%
Return on equity, FY2025: -657.1%

Financial strength

Current ratio: 1.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 35.6%

Valuation

P/E ratio: –
Price to sales: 2.14
Price to book: –
Dividend yield: –